Toremifene citrate
Product Name: Toremifene citrate;Fareston
CAS No.: 89778-27-8
M.F.: C32H36ClNO8
M.W.: 598.08
Packing: 1kg/foil bag
Assay: 99%
Melting Point: 158-164℃
Appearance: White powder
Molecular Formula: C26H28ClNO· C6H8O7
Molecular Weight: 598.09
Molecular Structure:

Melting Point: 158-164 º C
Boiling Point: 535.1 º C at 760 mmHg
Density: 1.045g/cm3
Refractive index: 1, 416-1, 418
Payment Method: Money Gram/Western Union T/T , Bitcoin .


Product description:

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

In 2007 the pharmaceutical company GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008